Innovation in bone healing and tissue repair

Christian Itin - Chairman

Christian Itin, PhD, serves as Chairman of the Company. From November 2012 to January 2016 he served as Cytos' Chief Executive Officer and Chairman of the Board of Directors. Prior to joining Cytos, Dr. Itin was President and Chief Executive Officer of Micromet Inc., a former Nasdaq-listed biopharmaceutical company, with its headquarters in Rockville, MD, USA and an R&D center in Munich, Germany, which was acquired in March 2012 by Amgen, Inc. for USD 1.16 billion. He spent 13 years with Micromet in a number of senior management roles, becoming CEO in 2004. Prior to joining Micromet in 1999, Dr. Itin co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA. He received a Diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he also performed post-doctoral research at the Biocenter of Basel University and at the Stanford University School of Medicine, CA, USA. Dr. Itin serves as Chairman of Autolus Ltd, London, UK and as a non-executive director of Kymab Ltd (Cambridge, UK). Christian Itin is a Swiss citizen and resident of Germany.

Leanna Caron

Mrs Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health. A healthcare executive for the past 20 years, she developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management through a progressive career at Merck Frosst Canada, Merck, Genzyme, and Sanofi. Mrs. Caron has served on the boards of WomenLead and CartiHeal. Mrs Caron received her Pharmacy degree from the University of Toronto and her MBA from Concordia and Cornell Universities.

Didier Cowling

Didier Cowling co-founded Kuros in early 2002 and has been its CEO since then. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Arnd Kaltofen

Arnd Kaltofen joined VI Partners in 2001 as a partner focusing on early-stage life science investments. Before that he built a team dedicated to venture capital transactions in the life science and health care industry for KPMG Corporate Finance (98-01). He gained his entrepreneurial experience in several medical device and e-health start-ups where he held various management positions (91-98). As an MD he started his professional career in a university hospital and in medical research (87-91). Current board memberships include Delenex Therapeutics AG, Jenavalve, Inc. and Ventaleon GmbH. In addition to his medical degree, Mr. Kaltofen also holds an MBA from Kellogg Graduate Business School, USA, and WHU Koblenz, Germany, as well as a Postgraduate Degree in Computer Sciences from TU Munich, Germany.

Jörg Neermann

Jörg Neermann, PhD, joined LSP as Partner in 2007. Dr. Neermann's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Dr. Neermann brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Dr. Neermann is currently a Director at Probiodrug, a publicly listed German biotech company active in the area of Alzheimer’s Disease. Dr. Neermann holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US.

Gerhard Ries

Gerhard Ries, PhD, is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharma industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was Co-founder and Managing Partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs and Leukocare. Dr. Ries holds a M.S. and a Ph.D. degree in Molecular Biology from the University of Basel and a M.S. degree in Biotechnology from the Fachhochschule Weihenstephan (Munich).

Harry Welten

Harry Welten, MBA, serves as Board member of the Company. From June 2010 to January 2016 he served as Executive Vice President and Chief Financial Officer of Cytos. He has more than 20 years of international senior executive experience, fourteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the Chief Financial Officer at Nitec Pharma AG in Reinach which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the Chief Financial Officer at Arpida AG which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a Director at UBS Warburg in New York following various senior positions within the UBS Group. Before joining UBS, he was with ABB and DaimlerChrysler. He is a member of the Board of Directors of Anokion, BiognoSYS AG, ProteoMediX, Horizon Pharma AG as well as of BioSupport AG. Furthermore, he is a member of the foundation council of HBM Fondation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Board

Christian Itin
Chairman

Christian Itin, PhD, serves as Chairman of the Company. From November 2012 to January 2016 he served as Cytos' Chief Executive Officer and Chairman of the Board of Directors. Prior to joining Cytos, Dr. Itin was President and Chief Executive Officer of Micromet Inc., a former Nasdaq-listed biopharmaceutical company, with its headquarters in Rockville, MD, USA and an R&D center in Munich, Germany, which was acquired in March 2012 by Amgen, Inc. for USD 1.16 billion. He spent 13 years with Micromet in a number of senior management roles, becoming CEO in 2004. Prior to joining Micromet in 1999, Dr. Itin co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA. He received a Diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he also performed post-doctoral research at the Biocenter of Basel University and at the Stanford University School of Medicine, CA, USA. Dr. Itin serves as Chairman of Autolus Ltd, London, UK and as a non-executive director of Kymab Ltd (Cambridge, UK). Christian Itin is a Swiss citizen and resident of Germany.

Leanna Caron

Mrs Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health. A healthcare executive for the past 20 years, she developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management through a progressive career at Merck Frosst Canada, Merck, Genzyme, and Sanofi. Mrs. Caron has served on the boards of WomenLead and CartiHeal. Mrs Caron received her Pharmacy degree from the University of Toronto and her MBA from Concordia and Cornell Universities.

Didier Cowling

Didier Cowling co-founded Kuros in early 2002 and has been its CEO since then. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Arnd Kaltofen

Arnd Kaltofen joined VI Partners in 2001 as a partner focusing on early-stage life science investments. Before that he built a team dedicated to venture capital transactions in the life science and health care industry for KPMG Corporate Finance (98-01). He gained his entrepreneurial experience in several medical device and e-health start-ups where he held various management positions (91-98). As an MD he started his professional career in a university hospital and in medical research (87-91). Current board memberships include Delenex Therapeutics AG, Jenavalve, Inc. and Ventaleon GmbH. In addition to his medical degree, Mr. Kaltofen also holds an MBA from Kellogg Graduate Business School, USA, and WHU Koblenz, Germany, as well as a Postgraduate Degree in Computer Sciences from TU Munich, Germany.

Jörg Neermann

Jörg Neermann, PhD, joined LSP as Partner in 2007. Dr. Neermann's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Dr. Neermann brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Dr. Neermann is currently a Director at Probiodrug, a publicly listed German biotech company active in the area of Alzheimer’s Disease. Dr. Neermann holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US.

Gerhard Ries

Gerhard Ries, PhD, is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharma industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was Co-founder and Managing Partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs and Leukocare. Dr. Ries holds a M.S. and a Ph.D. degree in Molecular Biology from the University of Basel and a M.S. degree in Biotechnology from the Fachhochschule Weihenstephan (Munich).

Harry Welten

Harry Welten, MBA, serves as Board member of the Company. From June 2010 to January 2016 he served as Executive Vice President and Chief Financial Officer of Cytos. He has more than 20 years of international senior executive experience, fourteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the Chief Financial Officer at Nitec Pharma AG in Reinach which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the Chief Financial Officer at Arpida AG which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a Director at UBS Warburg in New York following various senior positions within the UBS Group. Before joining UBS, he was with ABB and DaimlerChrysler. He is a member of the Board of Directors of Anokion, BiognoSYS AG, ProteoMediX, Horizon Pharma AG as well as of BioSupport AG. Furthermore, he is a member of the foundation council of HBM Fondation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York.